6059-44-5

Basic information

• Product Name: methyl 3-aminoalaninate
• CAS NO: 6059-44-5
• Molecular Formula: C₄H₁₀N₂O₂*2ClH
• Molecular Weight: 118.1344
• Mol File: 6059-44-5.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 210°C at 760 mmHg
• Flash Point: 100.5°C
• Density: 1.116g/cm³
• Vapor Pressure: 0.197mmHg at 25°C
• Refractive Index: 1.467
• CAS DataBase Reference: methyl 3-aminoalaninate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-aminoalaninate(6059-44-5)
• EPA Substance Registry System: methyl 3-aminoalaninate(6059-44-5)

Safety Data

• Hazardous Substances Data: 6059-44-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 515-94-6 (S)-2,3-diaminopropionic acid 
• 1482-97-9 (S)-2,3-diaminopropanoic acid hydrochloride 
• 515-94-6 2,3-diaminopropanoic acid 
• 54897-59-5 2,3-diaminopropanoic acid hydrochloride 

Downstream Products

• 227098-01-3 DL-2,3-bis{[3-(3,4-dimethoxyphenyl)acryloyl]amino}propionic acid methyl ester 
• 1181818-57-4 2-phenyl-1H-imidazoline-4-carboxylic acid methyl ester 
• 77087-60-6 methyl (S)-2-amino-3-tert-butoxycarbonylaminopropanoate 
• 224184-31-0 methyl DL-2,3-bis[((triphenylmethyl)thio)-acetamido]propionate 
• 1239503-28-6 methyl 2-[5-bromo-4-cyano-3-(2,4-dichlorophenyl)-2-thienyl]-4,5-dihydro-1H-imidazole-5-carboxylate 
• 2387-23-7 1,3-Dicyclohexylurea 
• 736971-53-2 methyl 2-[(2,6-dichlorophenyl)methyl]-2-imidazoline-5-carboxylate 
• 897932-28-4 DL-2,3-bis[(3,4,5-trimethoxybenzoyl)amino]propionic acid methyl ester 
• 459868-95-2 2,3-Bis-[(E)-3-(3,4-bis-methoxycarbonyloxy-phenyl)-acryloylamino]-propionic acid methyl ester 
• 897932-00-2 2,3-bis-(3,4,5-tris-methoxycarbonyloxy-benzoylamino)-propionic acid methyl ester 
• 897931-99-6 2,3-bis-(3,4-bis-methoxycarbonyloxy-benzoylamino)-propionic acid methyl ester 
• 897932-01-3 N,N-bis(3,4-dimethoxycarbonylcaffeoyl)-D,L-2,3-diaminopropionic acid methyl ester 
• 61040-20-8 (S)-methyl 3-amino-2-((tert-butoxycarbonyl)amino)propanoate 

Relevant articles and documents

Design and applications of new phosphine-free tetradentate Pd-catalyst: Regioselective C–H activation on 1-substituted 1,2,3-triazoles and indoles(NH-Free)

This article describes the synthesis of a new phosphine free tetradentate Pd catalyst using dl-2,3-diaminopropionic acid. The complex was characterized by Mass, IR, and 1H NMR. The catalyst is air stable at room temperature and non-hygroscopic. Application of this new catalyst to regioselective C–H activation on 1-substituted 1,2,3-triazole and indoles with aryl iodides to get corresponding C-5 and C-2 arylated products with satisfactory yields. All the products were characterized by spectroscopic studies.

Contrast enhancement agents and method of use thereof

A contrast agent composition and a method of diagnostic imaging are provided. The composition comprises a pharmaceutically acceptable carrier and a metal-complex comprising a ligand having structure (XXX): wherein R1, R2, R3/su

Fluorescent non-peptidic RGD mimetics with high selectivity for αvβ3 vs αiIbβ3 integrin receptor: Novel probes for in vivo optical imaging

Integrins are heterodimeric transmembrane protein receptors consisting of different α and β subunits. αvβ3 integrins are overexpressed on many tumor cells and tumor-associated angiogenic vessels, whereas αIIbβ3 is a receptor for, e.g., fibrinogen and mediates platelet aggregation. In this study, a near-infrared fluorescent imaging probe has been designed and synthesized by conjugating fluorescent dyes to a non-peptidic, pharmacophore-based ligand, based on a molecular modeling design approach. Affinity values were determined, and in vitro cell binding assays and preliminary in vivo xenograft studies in nude mice were performed to evaluate target binding. Competition assays revealed excellent binding and selectivity to αvβ3 compared to that for αIIbβ3. In vitro, the probe showed high target binding on αvβ3-positive M-21 cells and negligible binding to αvβ3-negative MCF-7 cells. In vivo, the tracer is able to image target expression in U-87 xenografts with a maximum signal-to-noise ratio (SNR) of 2.5:1 at 24 h after injection.